Peptilogics
Courtney Lonchena has over 20 years of experience in various roles within the clinical operations and development field. Courtney'smost recent role is as the Director of Clinical Development at Peptilogics, where they started in November 2022. Prior to that, they served as the Director of Clinical Operations at Ocugen, Inc. from May 2021 to October 2021. Courtney also held positions at NexImmune as the Associate Director of Clinical Operations from October 2020 to May 2021, and at Lung Biotechnology, PBC, United Therapeutics Corporation as the Associate Director of Clinical Operations for EVLP development from 2018 to 2020. Courtney also gained experience at AstraZeneca as the Evidence Delivery Associate Director from 2015 to 2018, and at Eliassen Group, contracted to Otsuka America Pharmaceuticals, Inc., as a Project Manager, SME, and Business Analyst from 2013 to 2014. Courtney started their career in 2002 at Janssen, Pharmaceutical Companies of Johnson and Johnson, serving as the Assistant Director of Clinical Operations until 2004. Throughout their career, Courtney has consistently shown their expertise in clinical operations and development, making their a valuable asset to any organization.
Courtney Lonchena has obtained an MBA in Pharmaceutical Studies from Fairleigh Dickinson University-Florham Campus. Additionally, Courtney has earned two Bachelor of Science degrees from the University of Pittsburgh in Chemistry and Psychology, respectively.
This person is not in any offices
Peptilogics
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.